Correction to: Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model

Xiaoyan Xu, Yaqin Sun, Xufeng Cen, Bing Shan, Qingwei Zhao, Tingxue Xie, Zhe Wang, Tingjun Hou, Yu Xue, Mengmeng Zhang, Di Peng, Qiming Sun, Cong Yi, Ayaz Najafov, Hongguang XiaProtein 2021 · DOI · OpenAlex

Introduction

This report summarizes key findings from a study published in Protein & Cell regarding the neuroprotective potential of Metformin. While primarily a correction notice for technical details in the original publication, the data underscores a significant mechanism: Metformin’s ability to mitigate Alzheimer’s disease pathologies by activating chaperone-mediated autophagy (CMA).

The Role of Chaperone-Mediated Autophagy (CMA)

Alzheimer’s disease is characterized by metabolic dysfunction and the accumulation of toxic protein aggregates. Chaperone-mediated autophagy (CMA) is a highly selective cellular degradation pathway that utilizes "chaperone" proteins, such as Hsc70, to identify specific substrates and deliver them to the lysosomal receptor Lamp2a for recycling. The researchers investigated whether Metformin could leverage this pathway to clear dysregulated metabolic enzymes.

Experimental Methodology

The study employed H4 human neuroglioma cells and transgenic Alzheimer’s mouse models. To isolate the role of CMA, researchers used:

  • Genetic Silencing: siRNA was used to knock down Hsc70 and Lamp2a.
  • Lysosomal Inhibition: Chemical inhibitors (Bafilomycin A1, Leupeptin) were used to confirm lysosomal degradation.
  • Interaction Assays: Co-Immunoprecipitation (Co-IP) and Proximity Ligation Assays (PLA) quantified the physical binding between target proteins and the CMA machinery.

Key Findings

Time-Dependent Degradation of Metabolic Enzymes

Metformin treatment was found to specifically target glycolytic enzymes HK2 and PKM2, which are often dysregulated in neurodegenerative states. Western blot analysis demonstrated a steady, time-dependent decrease in the levels of these proteins over a 24-hour period following Metformin administration.

Figure 5: Western blot analysis showing the time-dependent degradation of HK2 and PKM2 in H4 cells treated with Metformin over 24 hours.

Enhanced Interaction with CMA Machinery

A pivotal discovery was Metformin's role as a molecular "matchmaker." Proximity Ligation Assays (PLA) revealed that Metformin significantly increases the physical interaction between the target proteins (HK2/PKM2) and the CMA components Hsc70 and Lamp2a. This was visualized as a dramatic increase in red fluorescence in treated cells compared to controls.

Figure 6: Proximity Ligation Assay (PLA) demonstrating increased interaction (red signal) between target proteins and the CMA machinery upon Metformin treatment.

CMA Dependency

The study confirmed that Metformin’s effects are strictly dependent on an intact CMA pathway. When Hsc70 or Lamp2a were silenced via siRNA, Metformin failed to degrade HK2 and PKM2, identifying CMA as the essential "engine" for the drug's action.

Discussion and Limitations

While these results provide a compelling mechanism for Metformin's neuroprotective effects, several challenges remain for clinical translation. The transition from in vitro neuroglioma models and transgenic mice to the complex human brain environment is non-trivial. Furthermore, while short-term protein degradation is evident, the long-term safety and efficacy of sustained CMA activation in humans require further investigation. Future work will focus on the specific molecular "handshake" Metformin facilitates to enable even more targeted therapeutic interventions.

Summary updated

BibTeX
@inproceedings{xu2021correction,
  author = {Xiaoyan Xu and Yaqin Sun and Xufeng Cen and Bing Shan and Qingwei Zhao and Tingxue Xie and Zhe Wang and Tingjun Hou and Yu Xue and Mengmeng Zhang and Di Peng and Qiming Sun and Cong Yi and Ayaz Najafov and Hongguang Xia},
  title = {{Correction to: Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model}},
  booktitle = {Protein},
  year = {2021},
  doi = {10.1007/s13238-021-00873-4},
}

Loading related content...

Figure